Vor Biopharma Q1 2026 Earnings Wide EPS Miss Sends Stock Down 47 Amid Ongoing Clinical Development FBIN Q1 2026 Earnings Narrow EPS Miss on Flat Revenue as Stock Advances EP Q3 2025 Earnings Loss Per Share Reported Amid Ongoing Industry Headwinds Verrica Pharmaceuticals VRCA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Stage Continues ANI Pharmaceuticals Q1 2026 Earnings Major EPS Beat Belies Subdued Market Response NRXP Q1 2026 Earnings Revenueless Biotech Reports EPS Miss but Stock Surges 34